Logo

Immunic Reports Results of IMU-838 in P-II EMPhASIS Study in Patients with Relapsing-Remitting Multiple Sclerosis

Share this

Immunic Reports Results of IMU-838 in P-II EMPhASIS Study in Patients with Relapsing-Remitting Multiple Sclerosis

Shots:

  • The P-II EMPhASIS study involves assessing of IMU-838 in 210 patients randomized in 36 centers across 4 EU countries- 209 patients received at least one dose of IMU-838 vs PBO and 197 patients completed @24-wks. treatment period
  • The study resulted in meeting its 1EPs & 2EPs: 62% & 70% reduction in CUA MRI lesions up to @24wks. in patients receiving IMU-838 (45mg & 30mg qd). Rate of treatment-emergent AEs (42.9% vs 43.5%); rate of treatment withdrawals (5.0% vs 7.2%)
  • Additionally- the company has reported financial results of Q2’20 with $48.6M in cash and cash equivalents. IMU-838 is an orally available DHOD inhibitor- acts on activated T and B cells and leave other immune cells largely unaffected- allowing the immune system to stay functioning

 Ref: Immunic | Image: PRNewswire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions